Evidence map›Paper›PMID 38779851›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Clusters of cognitive performance predict long-term cognitive impairment in elderly patients with subjective memory complaints and healthy controls.

Adolfo Jiménez-Huete, Rafael Villino-Rodríguez, Mirla M Ríos-Rivera, Teresa Rognoni, Genoveva Montoya-Murillo, Carlota Arrondo, Carolina Zapata, María Cruz Rodríguez-Oroz, Mario Riverol, Alzheimer's Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Adolfo Jiménez-HueteDepartment of Neurology, Clínica Universidad de Navarra, Madrid, Spain.ORCID 0000-0001-7438-8763
Rafael Villino-RodríguezDepartment of Neurology, Clínica Universidad de Navarra, Madrid, Spain.
Mirla M Ríos-RiveraDepartment of Neurology, Clínica Universidad de Navarra, Madrid, Spain.
Teresa RognoniDepartment of Neurology, Clínica Universidad de Navarra, Madrid, Spain.
Genoveva Montoya-MurilloDepartment of Neurology, Clínica Universidad de Navarra, Madrid, Spain.
Carlota ArrondoDepartment of Neurology, Clínica Universidad de Navarra, Madrid, Spain.
Carolina ZapataDepartment of Neurology, Clínica Universidad de Navarra, Madrid, Spain.
María Cruz Rodríguez-OrozDepartment of Neurology, Clínica Universidad de Navarra, Madrid, Spain.
Mario RiverolDepartment of Neurology, Clínica Universidad de Navarra, Madrid, Spain.
Alzheimer's Disease Neuroimaging Initiative

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MICHAEL W WEINER · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
AbbVieAlzheimer's AssociationAlzheimer's Disease Neuroimaging InitiativeAlzheimer's Drug Discovery FoundationAraclon BiotechBioClinica, Inc.BiogenBristol-Myers Squibb CompanyCereSpir, Inc.CIHRCogstateDepartment of Defense W81XWH-12-2-0012Eisai Inc.Elan Pharmaceuticals, Inc.Eli Lilly and CompanyEuroImmun; F. Hoffmann-La Roche LtdFujirebioGE HealthcareGenentech, Inc.IXICO Ltd.Janssen Alzheimer Immunotherapy Research & Development, LLCJohnson & Johnson Pharmaceutical Research & Development LLC; LumosityMerck & Co., Inc.Meso Scale Diagnostics, LLCNeuroRx ResearchNeurotrack TechnologiesNIA NIH HHS U01 AG024904NIA NIH HHS U19 AG024904NIBIB NIH HHSNIH HHS U01 AG024904Novartis Pharmaceuticals CorporationPfizer Inc.Piramal ImagingTakeda Pharmaceutical CompanyTransition Therapeutics
6 · The paper itself

Abstract

introductionPatients with subjective memory complaints (SMC) may include subgroups with different neuropsychological profiles and risks of cognitive impairment.

methodsCluster analysis was performed on two datasets (n: 630 and 734) comprising demographic and neuropsychological data from SMC and healthy controls (HC). Survival analyses were conducted on clusters. Bayesian model averaging assessed the predictive utility of clusters and other biomarkers.

resultsTwo clusters with higher and lower than average cognitive performance were detected in SMC and HC. Assignment to the lower performance cluster increased the risk of cognitive impairment in both datasets (hazard ratios: 1.78 and 2.96; P DISCUSSION: This study provides evidence of the presence of cognitive clusters that hold biological significance and predictive value for cognitive decline in SMC and HC. HIGHLIGHTS: Patients with subjective memory complaints include two cognitive clusters. Assignment to the lower performance cluster increases risk of cognitive impairment. This cluster shows a pattern of biomarkers consistent with incipient Alzheimer's disease pathology. The same cognitive cluster structure is found in healthy controls. The effect of memory complaints on risk of cognitive decline is small and confounded.

Indexed as

Cognitive DysfunctionMemory DisordersNeuropsychological TestsAgedAmyloid beta-PeptidesBayes TheoremBiomarkersCluster AnalysisFemaleHippocampusHumansMaleMiddle AgedPeptide Fragmentstau ProteinsAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau ProteinsAlzheimer's diseaseBayesian model averagingbiomarkerscluster analysiscognitive impairmentneuropsychological profilessubjective memory complaints

Identifiers

PMID38779851
PMCPMC11247668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.